Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4

Introduction

The Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is a highly specific and potent therapeutic agent that targets the programmed death-ligand 1 (PD-L1) protein. This antibody has been extensively studied and has shown promising results in various pre-clinical and clinical trials. In this article, we will provide a detailed description of the structure, activity, and potential applications of this antibody.

Structure of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4

The Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is a monoclonal antibody that is produced by hybridoma technology. It is a fully humanized IgG1 antibody that specifically binds to the PD-L1 protein. The antibody has a molecular weight of approximately 150 kDa and is composed of two heavy chains and two light chains. The heavy chains consist of a constant region and a variable region, while the light chains consist of only a variable region. The variable regions of the antibody are responsible for its high specificity and binding affinity to PD-L1.

Activity of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4

The primary activity of the Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is to block the interaction between PD-L1 and its receptor, programmed cell death protein 1 (PD-1). PD-L1 is a key immune checkpoint protein that is overexpressed in various types of cancer cells. When PD-L1 binds to PD-1 on T cells, it suppresses the immune response and allows cancer cells to evade detection and destruction by the immune system. The Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 binds to PD-L1 and prevents its interaction with PD-1, thereby restoring the immune response against cancer cells.
In addition to its primary activity, the Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 has also been shown to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) against cancer cells. This means that the antibody can recruit immune cells and activate the complement system to directly kill cancer cells.

Applications of Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4

Therapeutic Target

The primary application of the Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is in cancer therapy. PD-L1 is overexpressed in a variety of cancers, including lung, breast, bladder, and melanoma. By targeting PD-L1, the antibody can enhance the immune response against these cancers and potentially lead to tumor regression. The antibody has been shown to be effective as a monotherapy and in combination with other cancer treatments, such as chemotherapy and other immunotherapies.
In addition to cancer therapy, the Anti-Human CD274/PD-L1/B7-H1 Monoclonal Antibody, 2.7A4 is also being investigated as a potential treatment for autoimmune diseases. PD-L1 is also expressed in autoimmune diseases, and blocking its interaction with PD-1 can prevent the suppression of the immune response and potentially alleviate symptoms of these diseases.